Skip to main content
Rosa Andrés Ejarque

Dr Rosa Andrés Ejarque

Senior Computational Biologist

Biography

Dr. Rosa Andrés Ejarque is a Senior Computational Biologist at the School of Cancer and Pharmaceutical Sciences, King's College London. She obtained her PhD in Biomedicine and Pharmacy at the University of Valencia in 2013.

Her research focuses on the computational characterisation of tumour-immune crosstalk across malignancies. In haematological cancers, she is particularly interested in the immunological underpinnings of disease progression along the MDS-AML continuum, with a specific focus on the role of regulatory T cells in immune evasion and risk stratification. In solid tumours, her work examines macrophage polarisation and functional heterogeneity in the microenvironments of triple negative breast cancer, ovarian cancer, and pancreatic ductal adenocarcinoma.

To address these questions she integrates single-cell RNA sequencing, multi-omics, and computational disease modelling approaches, with an emphasis on translating immune signatures into clinically meaningful disease frameworks.

    Research

    systems cancer immunology-banner
    Systems Cancer Immunology

    The main focus of the Systems Cancer Immunology (SCI) group is the role of immune system in the development of Myeloid Malignancies.

    News

    Outcomes of psoriasis treatment can be predicted by white blood cell response to test, scientists discover

    The way type 2 conventional dendritic cells (cDC2) respond to an in vitro test before the patient commences therapy can predict whether the therapy is going...

    Severe Psoriasis

      Research

      systems cancer immunology-banner
      Systems Cancer Immunology

      The main focus of the Systems Cancer Immunology (SCI) group is the role of immune system in the development of Myeloid Malignancies.

      News

      Outcomes of psoriasis treatment can be predicted by white blood cell response to test, scientists discover

      The way type 2 conventional dendritic cells (cDC2) respond to an in vitro test before the patient commences therapy can predict whether the therapy is going...

      Severe Psoriasis